IL6 and neoplasm: Myeloma progenitors in the BM microenvironment take advantage of both myeloma-cell-derived (autocrine) and tumour microenvironment-derived (paracrine) IL-6 released by non-malignant bystander cells such as bone marrow stromal cells (BMSCs).